Compare GSK Pharma with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs ASTRAZENECA PHARMA - Comparison Results

GSK PHARMA     Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA ASTRAZENECA PHARMA GSK PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 31.9 93.2 34.3% View Chart
P/BV x 12.7 26.3 48.4% View Chart
Dividend Yield % 1.2 0.0 -  

Financials

 GSK PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    GSK PHARMA
Mar-19
ASTRAZENECA PHARMA
Mar-18
GSK PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs3,5951,278 281.3%   
Low Rs1,253883 142.0%   
Sales per share (Unadj.) Rs184.7228.4 80.8%  
Earnings per share (Unadj.) Rs26.310.4 253.7%  
Cash flow per share (Unadj.) Rs29.216.3 179.3%  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs126.398.8 127.9%  
Shares outstanding (eoy) m169.4025.00 677.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x13.14.7 277.5%   
Avg P/E ratio x92.2104.2 88.4%  
P/CF ratio (eoy) x83.166.4 125.1%  
Price / Book Value ratio x19.210.9 175.5%  
Dividend payout %76.10-   
Avg Mkt Cap Rs m410,62627,008 1,520.4%   
No. of employees `0005.01.4 365.8%   
Total wages/salary Rs m5,3721,535 349.9%   
Avg. sales/employee Rs Th6,306.74,210.9 149.8%   
Avg. wages/employee Rs Th1,083.11,132.2 95.7%   
Avg. net profit/employee Rs Th898.0191.1 470.0%   
INCOME DATA
Net Sales Rs m31,2815,710 547.8%  
Other income Rs m1,023123 835.2%   
Total revenues Rs m32,3045,833 553.9%   
Gross profit Rs m6,009463 1,298.1%  
Depreciation Rs m486147 329.7%   
Interest Rs m60-   
Profit before tax Rs m6,540438 1,493.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m2870-   
Tax Rs m2,373179 1,326.4%   
Profit after tax Rs m4,454259 1,719.0%  
Gross profit margin %19.28.1 236.9%  
Effective tax rate %36.340.8 88.8%   
Net profit margin %14.24.5 313.8%  
BALANCE SHEET DATA
Current assets Rs m20,0613,209 625.1%   
Current liabilities Rs m14,5432,070 702.7%   
Net working cap to sales %17.620.0 88.4%  
Current ratio x1.41.6 89.0%  
Inventory Days Days5772 78.5%  
Debtors Days Days1435 40.3%  
Net fixed assets Rs m14,343790 1,814.8%   
Share capital Rs m1,69450 3,388.0%   
"Free" reserves Rs m19,7042,419 814.5%   
Net worth Rs m21,3982,469 866.6%   
Long term debt Rs m20-   
Total assets Rs m39,1134,605 849.3%  
Interest coverage x1,091.0NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.81.2 64.5%   
Return on assets %11.45.6 202.7%  
Return on equity %20.810.5 198.4%  
Return on capital %31.917.7 180.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m534300 178.3%   
Fx outflow Rs m7,0912,015 351.9%   
Net fx Rs m-6,557-1,715 382.3%   
CASH FLOW
From Operations Rs m3,99488 4,543.6%  
From Investments Rs m-1,433-94 1,531.4%  
From Financial Activity Rs m-3,584NA-  
Net Cashflow Rs m-1,023-6 17,950.9%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 50.7 75.0 67.6%  
Indian inst/Mut Fund % 10.2 0.3 3,400.0%  
FIIs % 23.8 15.7 151.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 9.1 169.2%  
Shareholders   102,036 12,856 793.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Flat; L&T and Tech Mahindra Top Losers(12:30 pm)

Share markets in India are presently trading on a volatile note. Sectoral indices are trading mixed with stocks in the capital goods sector and realty sector.

Related Views on News

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Nov 13, 2019 12:47 PM

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - VENUS REMEDIES COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS